NangioTx Inc

NangioTx’s flagship product is an injectable drug, V-10, that helps create new blood vessels to treat root canals. NangioTx' injectable hydrogel creates a tissue regenerative matrix. Additionally, V10 has shown animal efficacy in treating peripheral artery disease ($14B market) and a funded Phase I SBIR for efficacy in diabetic wound healing. Business model is to sell doses for $100 each at 90% profit margin (1 dose/root canal)